● Recruiting

Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)

Condition: Charcot-Marie-Tooth Disease Type 4J · Sponsor: Elpida Therapeutics SPC

PhasePhase 1/Phase 2

Planned participants8

Who can joinAll sexes, 3 Years to 20 Years

Healthy volunteersNo

About this study

First-in-human Phase 1/2, open-label study to evaluate the safety, tolerability, and efficacy of a single lumbar intrathecal dose of ELP-02 to individuals with CMT4J.

This description comes directly from the study's public registry record.

Talk to the study team

Rachel Thomas, RN · 1-833-335-7432 · studyinfo@elpidatx.com

Always discuss trial participation with your own doctor first.

Locations (2)

Stanford University	Palo Alto, California, United States	Recruiting
University of Iowa	Iowa City, Iowa, United States	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07447557